Gannex receives US IND Approval for NASH drug candidate, an FXR agonist
In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.